COSTEM 2019 | Improving AML outcomes

Charles Craddock

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, gives an overview of what we can expect to see from future acute myeloid leukemia (AML) clinical trials in the UK and how patient outcomes can be improved with the ongoing research that is currently underway. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video